Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 42%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is a global biopharmaceutical company that operates in two primary segments: Merck Pharmaceutical which focuses on research-based biopharmaceutical products and Merck Manufacturing which provides contract manufacturing and animal health products. The company has a positive outlook because of its diverse portfolio of products, including Keytruda, which is a major contributor to overall sales in the immuno-oncology market. Additionally, the company has a substantial vaccines business and is continuously investing in research and development to expand its pipeline and bring new products to market. Recent and upcoming milestones in the pipeline, such as data from Phase 3 trials for sac-TMT and potential approvals for enlicitide and Winrevair, have the potential to drive future revenue growth. However, the recent acquisition of Terns Pharma and potential patent losses for Keytruda may have a negative impact on earnings in the short term.

Bears say

Merck & Co is likely to face declining sales and margins due to the expiration of key patents for blockbuster drugs and potential challenges from generic and biosimilar companies. Positive pipeline data and potential approval of new drugs may provide a brief boost, but the company faces significant competition in various therapeutic areas. Additionally, macroeconomic conditions and a potential shift away from defensive stocks could impact Merck's stock price.

Merck (MRK) has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 42% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 19 analysts, Merck (MRK) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.